Patents by Inventor Peter York

Peter York has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190175591
    Abstract: Embodiments of the invention relate to particles of active substances, methods for preparing the particles, formulations containing the particles, and metered dose inhalers containing such particles or formulations. In one embodiment, a composition of an aerosol formulation is provided and contains a particulate active substance of non-micronized, solid particles having a mass median aerodynamic diameter of less than 10 ?m suspended in a hydrofluorocarbon fluid vehicle at a concentration within a range from about 0.2% w/v to about 5% w/v. The aerosol formulation exhibits a flocculation volume of about 85% or greater about 1 minute after mixing the particulate active substance and the hydrofluorocarbon fluid vehicle. The particulate active substance contains an alkaloid ergotamine, pharmaceutically acceptable salts thereof, analogues thereof, or derivatives thereof.
    Type: Application
    Filed: February 20, 2019
    Publication date: June 13, 2019
    Inventors: Andreas Kordikowski, Stephen Ernest Walker, Peter York
  • Patent number: 10251881
    Abstract: Embodiments of the invention relate to particles of active substances, methods for preparing the particles, formulations containing the particles, and metered dose inhalers containing such particles or formulations. In one embodiment, a composition of an aerosol formulation is provided and contains a particulate active substance of non-micronized, solid particles having a mass median aerodynamic diameter of less than 10 ?m suspended in a hydrofluorocarbon fluid vehicle at a concentration within a range from about 0.2% w/v to about 5% w/v. The aerosol formulation exhibits a flocculation volume of about 85% or greater about 1 minute after mixing the particulate active substance and the hydrofluorocarbon fluid vehicle. The particulate active substance contains an alkaloid ergotamine, pharmaceutically acceptable salts thereof, analogues thereof, or derivatives thereof.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: April 9, 2019
    Assignee: Nektar Therapeutics
    Inventors: Andreas Kordikowski, Stephen Ernest Walker, Peter York
  • Publication number: 20190083749
    Abstract: The needle-sized surgical tools used in arthroscopy, otolaryngology, and other surgical fields could become even more valuable to surgeons if endowed with the ability to navigate around sharp corners to manipulate or visualize tissue. A needle-sized bendable joint design that grants this ability. It can be easily interfaced with manual tools or concentric tube robots and is straightforward and inexpensive to manufacture. The bendable joint includes of a nitinol tube with several asymmetric cutouts, actuated by a tendon.
    Type: Application
    Filed: October 31, 2018
    Publication date: March 21, 2019
    Inventors: Philip J. Swaney, Peter York, Hunter B. Gilbert, Robert J. Webster, III, Arthur W. Mahoney, Patrick Wellborn
  • Patent number: 10188614
    Abstract: The present invention relates to active substances in particulate form, to methods for preparing them and to their uses. The present invention provides particulate powders, such as might be of use for delivery using a dry powder inhaler (DPI) or similar delivery device, having properties which may be beneficial to the DPI delivery process.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: January 29, 2019
    Assignee: Nektar Therapeutics
    Inventors: Peter York, Boris Yu Shekunov, Mahboob Ur Rehman, Jane Catherine Feeley
  • Publication number: 20180169060
    Abstract: Polymorphic forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) and a metabolite of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) are disclosed and characterized. Compositions and method for treatment of Alzheimer's disease that includes the polymorphic forms and metabolite of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73).
    Type: Application
    Filed: July 19, 2016
    Publication date: June 21, 2018
    Inventors: Linda Sharon Daintree, Daniel Mark Ledger, Lucy Anne Leonard, Peter York
  • Publication number: 20170318839
    Abstract: Embodiments of the invention provide a composition of a particulate coformulation which includes particles containing an active substance and an additive, wherein each particle contains a relative additive concentration increasing radially outwards from a particle center to a particle surface along a finite gradient. In one example, the particle surface is an additive-rich surface without a distinct physical boundary between the particle center and the particle surface. The relative additive concentration may have a continuous rate of change across the finite gradient. In some examples, an active substance:additive ratio of the particle surface is sufficiently low to form a protective surface layer around the active substance. Generally, the particle surface is free of the active substance.
    Type: Application
    Filed: July 18, 2017
    Publication date: November 9, 2017
    Inventors: Mazen H. Hanna, Peter York
  • Publication number: 20170273920
    Abstract: The present invention relates to active substances in particulate form, to methods for preparing them and to their uses. The present invention provides particulate powders, such as might be of use for delivery using a dry powder inhaler (DPI) or similar delivery device, having properties which may be beneficial to the DPI delivery process.
    Type: Application
    Filed: June 9, 2017
    Publication date: September 28, 2017
    Inventors: Peter York, Boris Yu Shekunov, Mahboob Ur Rehman, Jane Catherine Feeley
  • Patent number: 9700529
    Abstract: The present invention relates to active substances in particulate form, to methods for preparing them and to their uses. The present invention provides particulate powders, such as might be of use for delivery using a dry powder inhaler (DPI) or similar delivery device, having properties which may be beneficial to the DPI delivery process.
    Type: Grant
    Filed: April 13, 2016
    Date of Patent: July 11, 2017
    Assignee: Nektar Therapeutics
    Inventors: Peter York, Boris Yu Shekunov, Mahboob Ur Rehman, Jane Catherine Feeley
  • Publication number: 20170173006
    Abstract: Embodiments of the invention relate to particles of active substances, methods for preparing the particles, formulations containing the particles, and metered dose inhalers containing such particles or formulations. In one embodiment, a composition of an aerosol formulation is provided and contains a particulate active substance of non-micronized, solid particles having a mass median aerodynamic diameter of less than 10 ?m suspended in a hydrofluorocarbon fluid vehicle at a concentration within a range from about 0.2% w/v to about 5% w/v. The aerosol formulation exhibits a flocculation volume of about 85% or greater about 1 minute after mixing the particulate active substance and the hydrofluorocarbon fluid vehicle. The particulate active substance contains an alkaloid ergotamine, pharmaceutically acceptable salts thereof, analogues thereof, or derivatives thereof.
    Type: Application
    Filed: March 2, 2017
    Publication date: June 22, 2017
    Inventors: Andreas KORDIKOWSKI, Stephen Ernest WALKER, Peter YORK
  • Patent number: 9616060
    Abstract: Embodiments of the invention relate to particles of active substances, methods for preparing the particles, formulations containing the particles, and metered dose inhalers containing such particles or formulations. In one embodiment, a composition of an aerosol formulation is provided and contains a particulate active substance of non-micronized, solid particles having a mass median aerodynamic diameter of less than 10 ?m suspended in a hydrofluorocarbon fluid vehicle at a concentration within a range from about 0.2% w/v to about 5% w/v. The aerosol formulation exhibits a flocculation volume of about 85% or greater about 1 minute after mixing the particulate active substance and the hydrofluorocarbon fluid vehicle. The particulate active substance contains an alkaloid ergotamine, pharmaceutically acceptable salts thereof, analogs thereof, or derivatives thereof.
    Type: Grant
    Filed: August 4, 2014
    Date of Patent: April 11, 2017
    Assignee: Nektar Therapeutics
    Inventors: Andreas Kordikowski, Stephen Ernest Walker, Peter York
  • Publication number: 20170056325
    Abstract: A powder formulation, or pharmaceutical composition comprising or consisting of particles of an antimuscarinic agent, said particles being obtainable by supercritical anti-solvent (SAS) precipitation and having a D50 of 4 ?m or less and a D90 of 10 ?m or less. Methods of forming the formulation and composition are also disclosed, as are uses of the composition.
    Type: Application
    Filed: February 13, 2015
    Publication date: March 2, 2017
    Inventors: Daniel Mark Ledger, Linda Sharon Daintree, Peter York
  • Publication number: 20160346513
    Abstract: The needle-sized surgical tools used in arthroscopy, otolaryngology, and other surgical fields could become even more valuable to surgeons if endowed with the ability to navigate around sharp corners to manipulate or visualize tissue. A needle-sized bendable joint design that grants this ability. It can be easily interfaced with manual tools or concentric tube robots and is straightforward and inexpensive to manufacture. The bendable joint includes of a nitinol tube with several asymmetric cutouts, actuated by a tendon.
    Type: Application
    Filed: May 25, 2016
    Publication date: December 1, 2016
    Inventors: Philip J. Swaney, Peter York, Hunter B. Gilbert, Robert J. Webster, Arthur W. Mahoney, Patrick Wellborn
  • Publication number: 20160324806
    Abstract: The present invention relates to active substances in particulate form, to methods for preparing them and to their uses. The present invention provides particulate powders, such as might be of use for delivery using a dry powder inhaler (DPI) or similar delivery device, having properties which may be beneficial to the DPI delivery process.
    Type: Application
    Filed: April 13, 2016
    Publication date: November 10, 2016
    Inventors: Peter York, Boris Yu Shekunov, Mahboob Ur Rehman, Jane Catherine Feeley
  • Patent number: 9490079
    Abstract: Electrochemical energy storage devices such as electric double layer capacitors include flexible metal contact current collectors establishing electrical contact with a conductive housing and a conductive cover. The flexible current collector simplifies manufacturing of the device and avoids laser welding on the conductive housing. The manufacture devices are operable with a reduced direct current resistance by virtue of the flexible current collector.
    Type: Grant
    Filed: March 28, 2014
    Date of Patent: November 8, 2016
    Assignee: COOPER TECHNOLOGIES COMPANY
    Inventors: Peter York So, Chad David Johns, Kyle Yun-Su Kim
  • Patent number: 9339459
    Abstract: The present invention relates to active substances in particulate form, to methods for preparing them and to their uses. The present invention provides particulate powders, such as might be of use for delivery using a dry powder inhaler (DPI) or similar delivery device, having properties which may be beneficial to the DPI delivery process.
    Type: Grant
    Filed: September 18, 2012
    Date of Patent: May 17, 2016
    Assignee: NEKTAR THERAPEUTICS
    Inventors: Peter York, Boris Yu Shekunov, Mahboob Ur Rehman, Jane Catherine Feeley
  • Publication number: 20150366241
    Abstract: Embodiments of the invention provide a composition of a particulate coformulation which includes particles containing an active substance and an additive, wherein each particle contains a relative additive concentration increasing radially outwards from a particle center to a particle surface along a finite gradient. In one example, the particle surface is an additive-rich surface without a distinct physical boundary between the particle center and the particle surface. The relative additive concentration may have a continuous rate of change across the finite gradient. In some examples, an active substance:additive ratio of the particle surface is sufficiently low to form a protective surface layer around the active substance. Generally, the particle surface is free of the active substance.
    Type: Application
    Filed: August 31, 2015
    Publication date: December 24, 2015
    Inventors: Mazen H. HANNA, Peter YORK
  • Publication number: 20150279574
    Abstract: Electrochemical energy storage devices such as electric double layer capacitors include flexible metal contact current collectors establishing electrical contact with a conductive housing and a conductive cover. The flexible current collector simplifies manufacturing of the device and avoids laser welding on the conductive housing.
    Type: Application
    Filed: March 28, 2014
    Publication date: October 1, 2015
    Inventors: Peter York So, Chad David Johns, Kyle Yun-Su Kim
  • Patent number: 9120031
    Abstract: Embodiments of the invention provide a composition of a particulate coformulation which includes particles containing an active substance and an additive, wherein each particle contains a relative additive concentration increasing radially outwards from a particle center to a particle surface along a finite gradient. In one example, the particle surface is an additive-rich surface without a distinct physical boundary between the particle center and the particle surface. The relative additive concentration may have a continuous rate of change across the finite gradient. In some examples, an active substance: additive ratio of the particle surface is sufficiently low to form a protective surface layer around the active substance. Generally, the particle surface is free of the active substance.
    Type: Grant
    Filed: July 17, 2006
    Date of Patent: September 1, 2015
    Assignee: NEKTAR THERAPEUTICS
    Inventors: Mazen H. Hanna, Peter York
  • Publication number: 20140342002
    Abstract: Embodiments of the invention relate to particles of active substances, methods for preparing the particles, formulations containing the particles, and metered dose inhalers containing such particles or formulations. In one embodiment, a composition of an aerosol formulation is provided and contains a particulate active substance of non-micronized, solid particles having a mass median aerodynamic diameter of less than 10 ?m suspended in a hydrofluorocarbon fluid vehicle at a concentration within a range from about 0.2% w/v to about 5% w/v. The aerosol formulation exhibits a flocculation volume of about 85% or greater about 1 minute after mixing the particulate active substance and the hydrofluorocarbon fluid vehicle. The particulate active substance contains an alkaloid ergotamine, pharmaceutically acceptable salts thereof, analogues thereof, or derivatives thereof.
    Type: Application
    Filed: August 4, 2014
    Publication date: November 20, 2014
    Inventors: Andreas KORDIKOWSKI, Stephen Ernest WALKER, Peter YORK
  • Patent number: 8828359
    Abstract: Embodiments of the invention relate to particles of active substances, methods for preparing the particles, formulations containing the particles, and metered dose inhalers containing such particles or formulations. In one embodiment, a composition of an aerosol formulation is provided and contains a particulate active substance of non-micronized, solid particles having a mass median aerodynamic diameter of less than 10 ?m suspended in a hydrofluorocarbon fluid vehicle at a concentration within a range from about 0.2% w/v to about 5% w/v. The aerosol formulation exhibits a flocculation volume of about 85% or greater about 1 minute after mixing the particulate active substance and the hydrofluorocarbon fluid vehicle. The particulate active substance contains an alkaloid ergotamine, pharmaceutically acceptable salts thereof, analogs thereof, or derivatives thereof.
    Type: Grant
    Filed: June 3, 2013
    Date of Patent: September 9, 2014
    Assignee: Nektar Therapeutics
    Inventors: Andreas Kordikowski, Stephen Ernest Walker, Peter York